Treatment of severe bacteroides infections with parenteral clindamycin.
Clindamycin, by intravenous or intramuscular administration, was used in the treatment of 18 patients seriously ill with infections due to bacteroides organisms. In 17 cases there was a rapid favourable clinical response to treatment. No serious toxic effects were observed. This study appears to confirm previous in vitro evidence that clindamycin is presently the antibiotic of choice for such infections.
D000038:Abscess / Q000188:drug therapy / Q000209:etiology; D000328:Adult; D000368:Aged; D001062:Appendectomy; D001442:Bacteroides Infections / Q000188:drug therapy*; D002763:Cholecystectomy; D002981:Clindamycin / Q000008:administration & dosage / Q000627:therapeutic use; D003125:Colostomy; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D007044:Hysterectomy; D008034:Lincomycin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010538:Peritonitis / Q000188:drug therapy / Q000209:etiology; D011183:Postoperative Complications; D003668:Pressure Ulcer / Q000188:drug therapy / Q000209:etiology; D018805:Sepsis / Q000188:drug therapy / Q000209:etiology; D013156:Splenectomy; D013530:Surgical Wound Infection / Q000188:drug therapy
D002981:Clindamycin; D008034:Lincomycin